## Routine Site Visit Report

Principal Investigator			
First Name:			
Last Name:			
Study Information			
Study Information: Study Title:			
IRB Study #:			
-			
Study Visit Date			
Personnel:			
Research Staff Present:			
QIU Site Reviewer:			
Visit Summary:			
Strengths:			
Education			
Education:			
Feedback for HRPP:			
reedback for HRPP.			
<b>Overall Summary Evaluation</b>	on of Visit:		
Satisfactory, No QIU Recom	mendations		
Satisfactory with Recommendations			
Significant Findings (Comment and IRB Follow-up Required)			
Research Staff Roles and F	· ·	Yes	No
	rsonnel completed CITI training?		
•	on of delegation of research activities?	Ш	
c) Other comments?			
Sponsor:			
Federally Funded			
Other			
Industry			
Not Funded			

Regulatory Review:		No
a) Do study files include all sponsor/FDA/NIH correspondence (as applicable)?		
b) Are drug/device accountability records complete (as applicable)?		
c) Other comments?		
Sponsor:		
Federally Funded		
Other		
Industry		
Not Funded		
Study Characteristics:		No
a) Investigator Initiated?		
b) Investigator-held IND/IDE		
c) CTSI CRS		
CTSI CRS Involvement:	Yes	No
<ul> <li>a) Were all adverse events and/or protocol violations/incident reports reported to the PI?</li> </ul>		
Research Site:		
Parnassus		7
Mount Zion		 ]
China Basin		 ]
VAMC		
SFGH		
UCSF Affiliate		
Mission Bay		 ]
Other		

## Section A

1. Protocol Implementation: Subject recruitment,		Yes	No
	ning/enrollment process and records:		
•	Are recruitment activities per protocol?		
•	Are screening/ enrollment logs complete and up-to-date?		
•	Are subject withdrawals and dropouts documented?		
d)	Are entry criteria documented and eligibility confirmed?		
e)	Other comments?		
2 Info	ormed consent process, records, and documentation:	Yes	No
	Does the informed consent document (ICD) accurately reflect the study	163	INU
a)	protocol?		
b)	Is the consent process being implemented per protocol?		
c)	Are appropriate personnel conducting the consent process?		
d)	Is the consent process adequately documented for each participant in the		
	medical record/ research chart?		
e)	Is a signed/dated copy of the ICD on file for each person screened or enrolled?		
f)	Is a signed/dated copy of the HIPAA authorization on file for each person		
	screened/enrolled (as applicable)?		
g)	Is documentation on file that the Experimental Subject's Bill of Rights was provided (as applicable)?		
h)	Is documentation on file that consent process was ongoing (as applicable)?		
i)	Does the participant's MR include a signed copy of the ICD?		
•	Is the correct ICD version being used?		
j)	_		
k)	Other comments on ICD audit/IC process, records, documentations?		
3. Pro	tocol adherence:	Yes	No
a)	Are all study procedures being conducted according to the IRB-approved protocol?		
b)	Do reviewed CRFs demonstrate adherence to the approved IRB-approved		П
	protocol?		
c)	Other comments on CRF audit/protocol adherence?		
4. Rec	ord retention and data storage:	Yes	No
a)	Is management of on-site research records conducted according to IRB		
	approved protocol?		Ш
b)	Is management of on-site electronic research data conducted according to IRB-		
	approved protocol?		Ш
c)	Are desktop computers used for study activity encrypted?		
d)	Are laptop computers and mobile devices used for study activity encrypted?		
e)	Other comments?		

Section A comments:		
) +: D		
Section B		
1. IRB Post-Approval Communication	Yes	No
a) Were there any lapses in approval?		
b) Did any research activity occur during approval lapse?		
c) Were all modifications approved by the IRB prior to implementation?		
d) Other comments?		
Section B comments:		
Section C  Post-approval event reporting – adverse events (AE), violations, or incident reporting:	Yes	No
a) Is there a process in place to capture and document all occurrences?		
b) Were adverse event reports submitted to the IRB per HRPP guidelines?		
c) Were incident or violations reported to the IRB per HRPP guidelines?		
d) Other comments?		
Section C comments:		